Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02922296 · ClinicalTrials.gov registry record

Glucose Metabolism in Sickle Cell Disease

A clinical trial of Sickle Cell Disease and Diabetes Mellitus, sponsored by University of Illinois at Chicago.

Active
Registry status
75
Enrollment target
1
Study location

NCT02922296: Active study of Sickle Cell Disease and Diabetes Mellitus, sponsored by University of Illinois at Chicago.

NCT02922296 is a study of Sickle Cell Disease and Diabetes Mellitus that is active but no longer recruiting, run by University of Illinois at Chicago. The registered enrollment target is 75 participants, below the 292-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02922296, a study of Sickle Cell Disease and Diabetes Mellitus, is active but no longer recruiting, sponsored by University of Illinois at Chicago.

ACTIVE NOT RECRUITING
Registry status
75 participants
Enrollment target
1
Study location

Study Summary

The purpose of the study is to better understand how the body handles sugars glucose and fats, such as cholesterol and triglycerides in sickle cell disease, and what puts certain persons at risk to develop diabetes. This understanding may help us to find new treatments to control blood sugar and prevent diabetes in people with and without sickle cell disease (SCD). In this research, DNA and RNA will be isolated from blood cells. DNA will be used to find genes that cause or protect from diabetes, high cholesterol and high triglyceride, and RNA will be used for studies designed to find out how genes are doing their job of eventually producing proteins.

Primary Outcome

The investigator will use the ATP III guidelines for definition of metabolic syndrome. A combination of any three of the following criteria will lead to the designation of metabolic syndrome: * waist circumference \>102 cm (men) or \>88 cm (women) * triglycerides ≥150 mg/dL * HDL cholesterol \<40 mg/dL (men) or \<50 mg/dL (women) * blood pressure ≥130/≥85 mg/dL (or recorded diagnosis of hypertension and use of antihypertensives) * fasting glucose ≥110 mg/dL (or diagnosis of diabetes and use of

Study Locations (1)

Illinois

  • University of Illinois at Chicago - Chicago

Trial Details

FieldValue
Enrollment Target 75 participants
Start Date 2015-05-01
Est. Completion 2026-08-01
University of Illinois at Chicago

430 total trials

What the registry record for NCT02922296 still lists

NCT02922296 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 75 participants, a relatively small participant target, below the 292-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (74% lower).

The record links to 2 conditions, with Sickle Cell Disease appearing as the primary indexed condition, and to 0 interventions.

NCT02922296 reports a single indexed study location in Illinois.

Frequently Asked Questions

What is clinical trial NCT02922296 about?

NCT02922296 is a clinical study titled "Glucose Metabolism in Sickle Cell Disease". The purpose of the study is to better understand how the body handles sugars glucose and fats, such as cholesterol and triglycerides in sickle cell disease, and what puts certain persons at risk to develop diabetes. This understanding may help us to find new treatments to control blood sugar and pre...

What is the current status of trial NCT02922296?

This trial is currently active not recruiting. The enrollment target is 75 participants. The study started on 2015-05-01. Estimated completion is 2026-08-01.

What conditions does trial NCT02922296 study?

This clinical trial studies the following conditions: Sickle Cell Disease, Diabetes Mellitus.

Who is sponsoring clinical trial NCT02922296?

This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02922296 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Sickle Cell Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02922296's enrollment target sits among peer trials

75 81st of 213 higher than 133 of 213 other Sickle Cell Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Sickle Cell Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01535430 · 75 participants

    Assessment of Eloquent Function in Brain Tumor Patients

  • NCT01542879 · 75 participants · Phase 1

    Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer

  • NCT02232191 · 75 participants · Phase 2

    Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients

  • NCT02754544 · 75 participants · NA

    Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02922296, the US trial registry maintained by the National Library of Medicine. NCT02922296 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.